semaglutide class action in michigan digestive blockage gastrointestinal obstruction Subocclusive ileus following off-label high-dose semaglutide use in: Endocrinology, Diabetes & Metabolism Case Reports Volume 2025 Issue 4 (2025) Lawsuit filed against Ozempic Lawsuit: July 2026 Blindness

S.-licensed providers who evaluate treatment options and determine if compounded GLP-1/GIP medications are appropriate

Codes reflect CY2026 CPT (American Medical Association)

Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis

Collectively, the current patent landscape reflects strong commercial interest in luteolins anti-inflammatory and metabolic properties, yet significant opportunities remain in the areas of reproductive tissue-targeted delivery, fibrotic disorders, and fertility preservation

specializing in weight management, GLP-1 medication nutrition therapy, bariatric surgery, digestive health, and sustainable behavior change Madeline Orack, RDN Registered Dietitian Nutritionist